{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:39:06Z","timestamp":1791005946006,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T00:00:00Z","timestamp":1405900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2013-23897-104604-23"],"award-info":[{"award-number":["2013-23897-104604-23"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Heart Lung Foundation","award":["20080409"],"award-info":[{"award-number":["20080409"]}]},{"name":"Swedish Heart Lung Foundation","award":["20100419"],"award-info":[{"award-number":["20100419"]}]},{"name":"Swedish Heart Lung Foundation","award":["20080498"],"award-info":[{"award-number":["20080498"]}]},{"name":"Swedish Heart Lung Foundation","award":["20110406"],"award-info":[{"award-number":["20110406"]}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","award":["00556\u20132009"],"award-info":[{"award-number":["00556\u20132009"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","award":["20110120"],"award-info":[{"award-number":["20110120"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","award":["20090376"],"award-info":[{"award-number":["20090376"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","award":["20110610"],"award-info":[{"award-number":["20110610"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The prevalence of cardiovascular and non-cardiovascular co-morbidities and their relative importance for outcomes in heart failure with preserved ejection fraction (HFPEF) remain poorly characterized. This study aimed to investigate this.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Karolinska\u2013Rennes (KaRen) Study was a multinational prospective observational study designed to characterize HFPEF. Inclusion required acute HF, defined by the Framingham criteria, LVEF \u226545%, and NT-pro-BNP \u2265300\u2009ng\/L or BNP \u2265100\u2009ng\/L. Detailed clinical data were collected at baseline and patients were followed prospectively for 18 months. Predictors of the primary (HF hospitalization or all-cause mortality) and secondary (all-cause mortality) outcomes were assessed with multivariable Cox regression. A total of 539 patients [56% women; median (interquartile range) age 79 (72\u201384) years; NT-pro-BNP\/BNP 2448 (1290\u20134790)\/429 (229\u2013805) ng\/L] were included. Known history of HF was present in 40%. Co-morbidities included hypertension (78%), atrial fibrillation\/flutter (65%), anaemia (51%), renal dysfunction (46%), CAD (33%), diabetes (30%), lung disease (25%), and cancer (16%). The primary outcome occurred in 268 patients [50%; 106 deaths (20%) and 162 HF hospitalizations (30%)]. Important independent predictors of the primary and\/or secondary outcomes were age, history of non-cardiovascular syncope, valve disease, anaemia, lower sodium, and higher potassium, but no cardiovascular co-morbidities. Renin\u2013angiotensin system antagonist and mineralocorticoid receptor antagonist use predicted improved prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HFPEF was associated with higher age, female gender, hypertension, atrial fibrillation\/flutter, and numerous non-cardiovascular co-morbidities. Prognosis was determined by non-cardiovascular co-morbidities, but use of conventional heart failure medications may still be associated with improved outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.137","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T06:08:22Z","timestamp":1405922902000},"page":"992-1001","source":"Crossref","is-referenced-by-count":119,"title":["Association Between Cardiovascular vs. Non-Cardiovascular Co-Morbidities and Outcomes in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1093","volume":"16","author":[{"given":"Lars H.","family":"Lund","sequence":"first","affiliation":[{"name":"Karolinska Institutet, Department of Medicine , Stockholm ,","place":["Sweden"]},{"name":"Karolinska University Hospital, Department of Cardiology , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes \u00a0","place":["France"]},{"name":"LTSI , Universit\u00e9 Rennes 1, INSERM, 1099, Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[{"name":"INSERM , Clinical Investigation Center CIC-1414, Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Hage","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Medicine , Stockholm ,","place":["Sweden"]},{"name":"Karolinska University Hospital, Department of Cardiology , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Persson","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Clinical Sciences Danderyd , Stockholm ,","place":["Sweden"]},{"name":"Danderyd Hospital, Department of Cardiology , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Haugen-L\u00f6fman","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Medicine , Stockholm ,","place":["Sweden"]},{"name":"Karolinska University Hospital, Department of Cardiology , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Vladimir","family":"Ennezat","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, CHU Lille \u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sportouch-Dukhan","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie, CHU Montpellier \u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Drouet","sequence":"additional","affiliation":[{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Daubert","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes \u00a0","place":["France"]},{"name":"LTSI , Universit\u00e9 Rennes 1, INSERM, 1099, Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Medicine , Stockholm ,","place":["Sweden"]},{"name":"Karolinska University Hospital, Department of Cardiology , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,7,21]]},"reference":[{"key":"2026011921123267200_ejhf137-bib-0001","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/0735-1097(95)00381-9","article-title":"Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective","volume":"26","author":"Vasan","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026011921123267200_ejhf137-bib-0002","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026011921123267200_ejhf137-bib-0003","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ehj.2004.06.006","article-title":"Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey","volume":"25","author":"Lenzen","year":"2004","journal-title":"Eur Heart J"},{"key":"2026011921123267200_ejhf137-bib-0004","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/eurjhf\/hfp103","article-title":"The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis","volume":"11","author":"Somaratne","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011921123267200_ejhf137-bib-0005","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)","year":"2012","journal-title":"Europ Heart J"},{"key":"2026011921123267200_ejhf137-bib-0006","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"2026011921123267200_ejhf137-bib-0007","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure\u2014abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011921123267200_ejhf137-bib-0008","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2012.04.064","article-title":"What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?","volume":"60","author":"Campbell","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011921123267200_ejhf137-bib-0009","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin\u2013angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"2026011921123267200_ejhf137-bib-0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.2013.7967","article-title":"Aldosterone inhibition in patients with heart failure with preserved ejection fraction","volume":"310","author":"Lund","year":"2013","journal-title":"JAMA"},{"key":"2026011921123267200_ejhf137-bib-0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.321.7255.215","article-title":"Do patients with suspected heart failure and preserved left ventricular systolic function suffer from \u2018diastolic heart failure\u2019 or from misdiagnosis? A prospective descriptive study","volume":"321","author":"Caruana","year":"2000","journal-title":"BMJ"},{"key":"2026011921123267200_ejhf137-bib-0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.110.979203","article-title":"Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community","volume":"124","author":"Lam","year":"2011","journal-title":"Circulation"},{"key":"2026011921123267200_ejhf137-bib-0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011921123267200_ejhf137-bib-0014","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011921123267200_ejhf137-bib-0015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/eurjhf\/hfn025","article-title":"Rationale and design of the Karolinska\u2013Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction","volume":"11","author":"Donal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011921123267200_ejhf137-bib-0016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N Engl J Med"},{"key":"2026011921123267200_ejhf137-bib-0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"2026011921123267200_ejhf137-bib-0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"2026011921123267200_ejhf137-bib-0019","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"key":"2026011921123267200_ejhf137-bib-0020","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ehjci\/jes010","article-title":"Heart failure with a preserved ejection fraction: additive value of an exercise stress echocardiography","volume":"13","author":"Donal","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026011921123267200_ejhf137-bib-0021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.acvd.2013.11.002","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study","volume":"107","author":"Donal","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"2026011921123267200_ejhf137-bib-0022","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011921123267200_ejhf137-bib-0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011921123267200_ejhf137-bib-0024","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026011921123267200_ejhf137-bib-0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026011921123267200_ejhf137-bib-0026","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011921123267200_ejhf137-bib-0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"2026011921123267200_ejhf137-bib-0028","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026011921123267200_ejhf137-bib-0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"2026011921123267200_ejhf137-bib-0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","article-title":"Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011921123267200_ejhf137-bib-0031","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehm554","article-title":"Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study","volume":"29","author":"Tribouilloy","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011921123267200_ejhf137-bib-0032","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/eurheartj\/ehs305","article-title":"Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction","volume":"34","author":"Lund","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011921123267200_ejhf137-bib-0033","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients: a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026011921123267200_ejhf137-bib-0034","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921123267200_ejhf137-bib-0035","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.137","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/16\/9\/992\/66433836\/eurjhf_16_9_992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/16\/9\/992\/66433836\/eurjhf_16_9_992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:14:09Z","timestamp":1768875249000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/16\/9\/992\/8427671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,21]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,7,21]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.137","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9]]},"published":{"date-parts":[[2014,7,21]]}}}